And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
But it still has a long way to go with its islet cell therapies.
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.